Advertisement
Screener

Citadel Advisors LLC Historic Quarter Change: USA Bonds: Convertible Notes, New, 2021 Q4, Page 2

CITADEL ADVISORS LLC historic quarter change: USA Bonds: Convertible Notes, New

In convertible notes that pay a coupon (listed in the US), over 51 quarters from 2013-06-30 to 2026-03-31, CITADEL ADVISORS LLC opened 1,005 positions, added to 266, reduced 334 and sold out of 965.

  • Q4 2021: Stock TRAVERE THERAPEUTICS INC; Country of operation —; Class NOTE 2.500% 9/1; Principal before $0.
  • Q4 2021: Stock 8X8 INC NEW; Country of operation —; Class NOTE 0.500% 2/0; Principal before $0.
  • Q4 2021: Stock ZYNGA INC; Country of operation —; Class NOTE 0.250% 6/0; Principal before $0.
  • Q4 2021: Stock ENCORE CAP GROUP INC; Country of operation —; Class NOTE 3.250%10/0; Principal before $0.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1423053), 51 quarters: Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q4 2023 (2023-09-30 to 2023-12-31, filed 2024-02-14); Q3 2023 (2023-06-30 to 2023-09-30, filed 2023-11-14); Q2 2023 (2023-03-31 to 2023-06-30, filed 2023-08-14); Q1 2023 (2022-12-31 to 2023-03-31, filed 2023-05-15); Q4 2022 (2022-09-30 to 2022-12-31, filed 2023-02-14); Q3 2022 (2022-06-30 to 2022-09-30, filed 2022-11-14); Q2 2022 (2022-03-31 to 2022-06-30, filed 2022-08-15); Q1 2022 (2021-12-31 to 2022-03-31, filed 2022-05-16); Q4 2021 (2021-09-30 to 2021-12-31, filed 2022-02-14); Q3 2021 (2021-06-30 to 2021-09-30, filed 2021-11-15); Q2 2021 (2021-03-31 to 2021-06-30, filed 2021-08-16); Q1 2021 (2020-12-31 to 2021-03-31, filed 2021-05-17); Q4 2020 (2020-09-30 to 2020-12-31, filed 2021-02-16); Q3 2020 (2020-06-30 to 2020-09-30, filed 2020-11-16); Q2 2020 (2020-03-31 to 2020-06-30, filed 2020-08-14); Q1 2020 (2019-12-31 to 2020-03-31, filed 2020-05-15); Q4 2019 (2019-09-30 to 2019-12-31, filed 2020-02-14); Q3 2019 (2019-06-30 to 2019-09-30, filed 2019-11-14); Q2 2019 (2019-03-31 to 2019-06-30, filed 2019-08-14); Q1 2019 (2018-12-31 to 2019-03-31, filed 2019-05-15); Q4 2018 (2018-09-30 to 2018-12-31, filed 2019-02-14); Q3 2018 (2018-06-30 to 2018-09-30, filed 2018-11-13); Q2 2018 (2018-03-31 to 2018-06-30, filed 2018-08-10); Q1 2018 (2017-12-31 to 2018-03-31, filed 2018-05-11); Q4 2017 (2017-09-30 to 2017-12-31, filed 2018-02-09); Q3 2017 (2017-06-30 to 2017-09-30, filed 2017-11-09); Q2 2017 (2017-03-31 to 2017-06-30, filed 2017-08-11); Q1 2017 (2016-12-31 to 2017-03-31, filed 2017-05-12); Q4 2016 (2016-09-30 to 2016-12-31, filed 2017-02-10); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-10); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-13); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-18); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2009-12-31.

QuarterStockCountry of operationClassPrincipal beforePrincipal afterShare changeValue beforeValue afterValue changeFiled
Q4 2021TRAVERE THERAPEUTICS INC
CUSIP 761299AB2
—NOTE 2.500% 9/1$0$5,000,000+5,000,000$0$5,490+$5,4902022-02-14
Q4 20218X8 INC NEW
CUSIP 282914AB6
—NOTE 0.500% 2/0$0$5,000,000+5,000,000$0$5,014+$5,0142022-02-14
Q4 2021ZYNGA INC
CUSIP 98986TAB4
—NOTE 0.250% 6/0$0$3,490,000+3,490,000$0$3,770+$3,7702022-02-14
Q4 2021ENCORE CAP GROUP INC
CUSIP 292554AM4
—NOTE 3.250%10/0$0$2,000,000+2,000,000$0$3,288+$3,2882022-02-14
Q4 2021NEUROCRINE BIOSCIENCES INC
CUSIP 64125CAD1
—NOTE 2.250% 5/1$0$2,000,000+2,000,000$0$2,512+$2,5122022-02-14
Q4 2021NEOGENOMICS INC
CUSIP 64049MAA8
—NOTE 1.250% 5/0$0$1,500,000+1,500,000$0$1,783+$1,7832022-02-14
Q4 2021PEGASYSTEMS INC
CUSIP 705573AB9
—NOTE 0.750% 3/0$0$1,500,000+1,500,000$0$1,599+$1,5992022-02-14
Q4 2021ETSY INC
CUSIP 29786AAL0
—NOTE 0.125% 9/0$0$1,000,000+1,000,000$0$1,344+$1,3442022-02-14
Q4 2021LIVE NATION ENTERTAINMENT IN
CUSIP 538034AU3
—NOTE 2.000% 2/1$0$1,000,000+1,000,000$0$1,326+$1,3262022-02-14
Q4 2021NRG ENERGY INC
CUSIP 629377CG5
—DBCV 2.750% 6/0$0$1,000,000+1,000,000$0$1,185+$1,1852022-02-14
Q4 2021INSMED INC
CUSIP 457669AA7
—NOTE 1.750% 1/1$0$500,000+500,000$0$513+$5132022-02-14
Q4 2021LOGAN RIDGE FINANCE CORP
CUSIP 14054R403
—5.75% NT CV 22$0$20,850+20,850$0$21+$212022-02-14
Q4 2021READY CAPITAL CORP
CUSIP 75574U200
—7% CN SR NT 2023$0$12,050+12,050$0$13+$132022-02-14